A method for producing a flurane complex, comprising the steps of producing an aqueous solution of sulfobutylether--cyclodextrin (SBECD); controlling the temperature of said solution to a temperature of from 2 to 15 C.; adding the flurane to the aqueous solution; allowing the solution to react to produce the complex; and separating the complex.

A method for producing a flurane complex, comprising the steps of producing an aqueous solution of sulfobutylether--cyclodextrin (SBECD); controlling the temperature of said solution to a temperature of from 2 to 15 C.; adding the flurane to the aqueous solution; allowing the solution to react to produce the complex; and separating the complex.

Provided are topical analgesic compositions and methods of preparing topical analgesic compositions comprising a stable nano-encapsulating matrix film. The topical analgesic compositions and methods of preparing topical analgesic compositions may be suited for roll-on applicators. Topical analgesic compositions may include 12 to 16 wt. % menthol; 4 to 8 wt. % camphor; 2 to 15 wt. % film-forming polymer; and 50 to 70 wt. % solvent. To be used in a roll-on applicator, the topical analgesic composition has a viscosity from 800 to 1400 centipoise.

The invention is directed to a method for identifying a candidate anti-glioma drug that is a mitochondrial F.sub.1F.sub.o ATP Synthase c-subunit leak channel opener, the method comprising: a. providing an admixture comprising: i. a candidate drug; ii. a submitochondrial vesicle (SMV) preparation; and iii. an H.sup.+ probe, wherein the H.sup.+ probe remains outside of the SMV(s); b. contacting the admixture with ATP; c. measuring a level of H.sup.+ outside of the SMV(s) via the H.sup.+ probe; d. comparing the level of H.sup.+ at step c) with a level of H.sup.+ in a control admixture lacking the candidate drug; and identifying the drug as a candidate anti-glioma drug that is a mitochondrial F.sub.1F.sub.o ATP Synthase c-subunit leak channel opener, when the level of H.sup.+ is higher compared to the level of H.sup.+ in the control admixture; or identifying that the drug is not a candidate anti-glioma drug that is a mitochondrial F.sub.1F.sub.o ATP Synthase c-subunit leak channel opener, when the level of H.sup.+ is the same or lower compared to the level of H.sup.+ in the control admixture.

The invention is directed to a method for identifying a candidate anti-glioma drug that is a mitochondrial F.sub.1F.sub.o ATP Synthase c-subunit leak channel opener, the method comprising: a. providing an admixture comprising: i. a candidate drug; ii. a submitochondrial vesicle (SMV) preparation; and iii. an H.sup.+ probe, wherein the H.sup.+ probe remains outside of the SMV(s); b. contacting the admixture with ATP; c. measuring a level of H.sup.+ outside of the SMV(s) via the H.sup.+ probe; d. comparing the level of H.sup.+ at step c) with a level of H.sup.+ in a control admixture lacking the candidate drug; and identifying the drug as a candidate anti-glioma drug that is a mitochondrial F.sub.1F.sub.o ATP Synthase c-subunit leak channel opener, when the level of H.sup.+ is higher compared to the level of H.sup.+ in the control admixture; or identifying that the drug is not a candidate anti-glioma drug that is a mitochondrial F.sub.1F.sub.o ATP Synthase c-subunit leak channel opener, when the level of H.sup.+ is the same or lower compared to the level of H.sup.+ in the control admixture.

This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

The present invention provides compositions and methods for treating a dermatological disorder or disease.

The present invention provides compositions and methods for treating a dermatological disorder or disease.

The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.